Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
APPROACH: Perioperative vs Postoperative Bevacizumab in Colorectal Liver Metastases
NCT01632722Phase 2
Key facts
- Status
- Completed
- Start
- Jun 2012
- Primary completion
- May 2018
- Countries
- 1
- Sponsor
- Yonsei University
- Modality
- Monoclonal Antibodies
- Drugs
- bevacizumab
- Conditions
- colorectal cancer (CRC)
01
Overview
Phase 2, randomised, open-label trial of bevacizumab in colorectal cancer (CRC) (2 arms), sponsored by Yonsei University. Primary endpoint: 2 years recurrence-free survival. Started Jun 2012; status: completed.
02
Design
2 arms- Study design
- RandomizedOpen-label
Postoperative Arm
Surgery followed by mFOLFOX/FOLFIRI + Bevacizumab
Perioperative Arm
Preoperative mFOLFOX/FOLFIRI + Bevacizumab followed by Surgery and Postoperative mFOLFOX/FOLFIRI + Bevacizumab
03
Endpoints
Primary
2 years recurrence-free survival
Beyond the preview
Go deeper on NCT01632722.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01632722.